Precision BioSciences

Precision BioSciences is a clinical-stage gene editing company headquartered in Durham, NC, developing a new class of medicines using its proprietary ARCUS genome editing technology. Listed on Nasdaq (DTIL), the company focuses on in vivo gene editing with the goal of overcoming and potentially curing genetic diseases. Its ARCUS platform is designed for high precision in therapeutic applications.